| COMMENTARY |
|
| Year : 2019 | Volume
: 2
| Issue : 1 | Page : 19-21 |
|
|
Resurgence of role of radiotherapy in neoadjuvant treatment of pancreatic cancer
Rohit Avinash Vadgaonkar, Kaustav Talapatra
Department of Radiation Oncology, Kokilaben Dhirubhai Ambani Hospital, Mumbai, India
Correspondence Address:
Dr. Kaustav Talapatra
Department of Radiation Oncology, Kokilaben Dhirubhai Ambani Hospital, Four Bungalows, Andheri (W), Mumbai 400 053
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/JCO.JCO_23_18
|
|
|
Borderline resectable pancreatic cancer (BRPC) is a clinically distinguished malignancy. With limited role of aggressive surgical intervention, neoadjuvant treatment is warranted. Various studies and their meta-analysis addressing this issue have shown limited benefit. However, recently two prospective multiple randomized trials have evaluated benefit of neoadjuvant chemoradiotherapy in BRPC with a positive clinical response. This article gives a brief insight into these studies and discusses future prospects for role of radiation in neoadjuvant setting in pancreatic cancer. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
